🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Psychedelic Study: Cybin announced Phase II results for CYB003, their proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single dose compared to placebo. $CYBN

News: Clearmind Medicine | $CMND Entered into a clinical trial agreement with Johns Hopkins Medicine, to conduct their Phase I/IIa clinical trial of their proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder. psychedelicfinance.com/articles/clear…

Psychedelic medicines are one of the most exciting areas of drug discovery. And now, a new clinical trial is showing even more evidence for their therapeutic potential. A closer look at CybinInc's latest results: thenew.money/article/cybin-…

Psychedelics have long been seen as the potential next big breakthrough in biotech. And with overwhelming evidence for their therapeutic potential mounting, the first formal drug approval in North America is looking closer than ever. thenew.money/article/psyche…

Psychedelics have long been seen as the potential next big breakthrough in biotech. But for the first time ever, psychedelic therapeutics are finally getting closer to being approved drugs. $MNMD $CYBN $CMPS $ATAI Gilgamesh Pharma Lykos Therapeutics thenew.money/article/psyche…

One of the founders of Google is taking on an ambitious new venture: turning psychedelics into therapeutics. thenew.money/article/google…

Ketamine may have therapeutic potential for something new: neuropathic pain. And Mira Pharmaceuticals is at the centre of it. $MIRA The New Money thenew.money/article/mira-p…

There's a new Phase III clinical trial from CybinInc launching to validate psychedelic medicines as a therapeutic for treating mental health conditions. Could it become the first approved psychedelic drug in the United States of America? $CYBN thenew.money/article/cybin-…

There's a new Phase III clinical trial from CybinInc launching to validate psychedelic medicines as a therapeutic for treating mental health conditions. Could it become the first approved psychedelic drug in the United States of America? $CYBN thenew.money/article/cybin-…

Introducing: Trends Discover the emerging trends that are moving markets and the bets being made by some of the world's best investors. thenew.money/trends

Introducing: Psychedelic Stocks Psychedelics have a long history of therapeutic potential. Now, they might be getting closer to finally becoming approved medicines. Track the performance of public psychedelic drug developers. $ATAI $CMPS $MNMD $CYBN thenew.money/trend/psychede…

The United States Department of Veteran Affairs is funding its first psychedelic medicine research study in seven decades. And it's focused on MDMA for PTSD and alcohol use disorder in veterans. thenew.money/article/theres…

More: thenew.money/article/sprava…

Breaking: Psychedelic pharmaceutical company Atai Life Sciences has reported promising results for treating Alcohol Use Disorder with their synthetic DMT formulation. atai Life Sciences $ATAI

There’s been a lot of excitement about psychedelics in the public markets. But, is DMT about to become the next breakthrough compound to change the future of pharmaceuticals? $ATAI $GHRS thenew.money/article/the-dm…